1 The selectivity profiles of the muscarinic receptor antagonists dicyclomine and trihexypbenidyl have been examined in binding and functional studies and compared with those of pirenzepine and atropine. Thus, the drugs appeared to discriminate between the Ml (cortical) and the peripheral muscarinic subtypes (cardiac and glandular). However, atropine displayed similar affinities for either subtype with IC50s varying only slightly (1.6-4.6 nM). The rank order of selectivity was: pirenzepine > dicyclomine > trihexyphenidyl > atropine. 4 Mirroring the binding data, pirenzepine, dicyclomine and trihexyphenidyl showed a tenfold greater ability at inhibiting M,-receptor mediated ganglionic responses (McN A-343 pressor effect in pithed rats and nictitating membrane contraction in cats) than at inhibiting peripheral muscarinic responses in the heart and cardiovascular smooth muscle (vagal bradycardia in rats and cats and vagally-induced vasodilatation in cats).
Introduction
Heterogeneity among muscarinic receptors was first been obtained with the use ofthe selective M1 antagonnoted by Goyal & Rattan (1978) in the lower oesoist pirenzepine, a hydrophilic tricyclic compound phageal sphincter, a preparation in which vagal which readily differentiates muscarinic subtypes stimulation and exogenous muscarinic agonists elicit owing to its markedly higher affinity for the Ml opposite responses. Studies on agonist binding to receptor (Hammer et al., 1980; Watson et al., 1982) .
membranes have confirmed the original observation Among the many muscarinic antagonists available, demonstrating the presence of heterogeneous musdicyclomine (Luber-Narod & Potter, 1983; Marchi & carinic receptor populations in discrete brain areas Raiteri, 1985) , and trihexyphenidyl (Tien & Wallace, (Birdsall et al., 1978) and in peripheral tissues. Perhaps 1985), whose structures are unrelated to pirenzepine, the clearest evidence for subclassifying muscarinic have been shown to have features typical of M, receptors into subtypes, now termed Ml and M2, has antagonists, but a systematic investigation of their biochemical and pharmacological properties has not been performed. It was of interest therefore to compare the in vitro binding characteristics of these muscarinic antagonists and to evaluate their properties in functional responses. Parallel experiments, performed with atropine and pirenzepine, have yielded a coherent picture on the selective profile of these known muscarinic antagonists.
This paper is an extension ofresults which have been communicated to the British Pharmacological Society .
Methods
Male rats of the Sprague-Dawley strain (200-300g; Charles River, Italy) and cats (3-4 kg; Al Serio Breeding, Italy) of either sex were used for these experiments.
In vitro radioligand binding studies Rats were killed by cervical dislocation. Tissues were removed, cleaned and homogenized (w/v: cerebral cortex 1:200, submandibular gland 1: 150, total heart 1:300) with an Ultra-Turrax at maximal speed for 30 s followed by a Potter-Elvehjem (15 strokes) in Na'-Mg2+-HEPES buffer pH 7.4 (100mM NaCl, 10mM MgCl2, 20mM HEPES) and filtered through two layers of cheesecloth.
Binding curves for the different compounds were derived indirectly from competition experiments against 0.5 nM (Heinzel, 1982) and corrected to allow for competition with the radioligand using the equation: corr. IC5o = IC5O/(1 + [*C]/*KD) where (*CJ and *KD represent the concentration and the dissociation constant of the radioligand used, respectively (Cheng & Prusoff, 1973) . The KDs for NMS were 0.25 nM for the submandibular gland (Hammer et al., 1980) and 0.6 nM for the heart (data from this laboratory). For PZ, the KD value was found to be 14 nM for labelling of the M,-receptor subtype in the cerebral cortex under our experimental conditions.
Hill coefficients (nH) were calculated by linear regression analysis and analysed for statistical deviation from unity.
Pharmacological experiments
Rats were lightly anaesthetized with ether; after cannulation of the trachea they were pithed by introducing a sharp-pointed rod from the left orbit through the atlas. The rod penetrated about 3 cm into the spinal cord. Artificial respiration was provided immediately by means of a Bird respirator (80 strokes min '). A femoral vein and the left carotid artery were cannulated for the administration of drugs and the recording of arterial pressure, respectively. Heart rate was calculated from ECG recordings. The right vagus nerve was stimulated by placing bipolar platinum electrodes around the peripheral stump. The characteristics of stimulation were: 10V (supramaximal), 10 Hz, 2 ms duration, for 30 s. Antagonists were given intravenously 2min before vagal or DR2 values, i.e. the dose ofantagonist causing a two fold shift of the agonist dose-response curve, were obtained from the intercept on the abscissa scale ofthe regression line relating the log dose of antagonist to the log of the dose-ratio -1.
Drugs
[3H]-PZ (84 Ci mmol ') and rH]-NMS (84.8 Cimmol ') were purchased from New England Nuclear, The binding curves of the same drugs for the muscarinic receptors of submandibular gland and heart were obtained using [3H]-NMS (Figure 1 ). The affinity values and Hill coefficients calculated from the binding data are given in Table 1 . Pirenzepine, trihexyphenidyl and dicyclomine discriminated between muscarinic receptors in the different organs and showed similar selectivity patterns. The compounds displayed the highest affinity for the muscarinic receptors in the cerebral cortex with their affinity values varying only narrowly (3.7-14 nM). Although they exhibited intermediate affinity for the submandibular gland, there was greater disparity in their corr. IC50 values (17, 13 and 210 nm for trihexyphenidyl, dicyclomine and pirenzepine, respectively). The compounds displayed the lowest affinity for the muscarinic receptor of the heart with large differences in their corr. IC50 values (31 and 95 nm for trihexyphenidyl and dicyclomine, respectively; 500 nM for pirenzepine). Dicyclomine was unique in showing an almost 8 fold difference in selectivity between the glandular and heart subtypes.
As is now well known, atropine presented essentially no selectivity for the different muscarinic receptors. This is illustrated by the close apposition of its binding curves in the three tissues ( Figure 1 ) and the narrow, albeit potent, affinity range (1.6-4.6 nM). The affinity ratios between heart and cerebral cortex, shown in Table 1 , give an estimate of the selectivity of the drugs. The rank order of selectivity was: pirenzepine>dicyc-lomine > trihexyphenidyl > atropine. In the submandibular gland and heart, linear regression analysis of the concentration-occupancy curves for antagonists indicated that the experimental data followed the law of mass action (nH-1; Table 1 ). In contrast, in the cerebral cortex, except for pirenzepine (nHl 1), the other three compounds had nH values ranging from 1.16 to 1.37 which were significantly different from unity. This behaviour might be related to the high affinity that these compounds show for the Ml muscarinic receptor in the cerebral cortex, i.e. appreciable amounts are bound at low concentrations so that the free concentration values given on the abscissa scale are distorted by compound depletion.
McN-A-343 pressor action in the pithed rat Intravenous administration of the muscarinic ganglionic stimulant McN-A-343 in the pithed rat caused a small decrease ofmean blood pressure followed by a sharp pressor response. This latter effect, which is thought to be mediated through the Ml subtype , was dose-related within the range 30 to 350 pg kg'- (Figure 2) . The muscarinic antagonists were tested for their ability to inhibit the pressor response ofa dose ofMcN-A-343 (300 pg kg-' i.v.) which increased blood pressure by 90% of maximal (A 95 ± 6 mmHg). All caused a dose-related reduction of the vasoconstrictor action of the agonist. Their potencies, expressed as ID50s, are shown in Table 2 . The ID50s of pirenzepine and atropine were similar (12 and 8.7 pg kg-, respectively) while those of trihexyphenidyl and dicyclomine (54 and 418 pLg kg-', respectively) indicated a 5-35 fold weaker inhibitory action. The nature of the antagonism exerted by the muscarinic antagonists was defined by the shifts in the dose-response curves to McN-A-343 in the presence of various doses of each antagonist. An experiment depicting the shifts produced by graded doses of pirenzepine is seen in Figure 2 . This compound, as well as the other antagonists, produced parallel rightward shifts without depressing the maximum. Schild plots (Arunlakshana & Schild, 1959) of these data are shown in Figure 3 . With the limitations inherent in in vivo assays, in which equilibrium conditions may not be reached, all the muscarinic antagonists examined acted as competitive antagonists. Calculations ofDR2, that is, the dose required to produce a two fold rightward shift in the agonist dose-response curve, provided the following values (pg kg-', with 95% confidence limits): pirenzepine 4.7 (3.8-5.8); trihexyphenidyl 11.9 (7.0-20.2); dicyclomine 108 (86-135); atropine 2.9 (1.7-4.9).
The DR2 estimates, particularly for trihexphenidyl and dicyclomine, were lower than the ID50 values, a finding which is not unexpected since determination of ID50 is not corrected for competition with the agonist. However, the order ofpotency ofmuscarinic antagonists was the same with either procedure employed. 343 pressor activity (IDMs of 6.9 and 8.7 gg kg-', respectively), the other antagonists weakly inhibited the atrial slowing with IDMs ranging from 313 pg kg-' for trihexyphenidyl to 3089 pg kg-' for dicyclomine.
The ratio between the ID_0s of the compounds in antagonizing the vagal bradycardia and the McN A-343 pressor increase, shown in Table 2 , provided an estimate of their selectivity for the M1 subtype. Pirenzepine showed the greatest discrimination between the muscarinic-mediated responses, its ratio being 40, while trihexyphenidyl and dicyclomine showed moderate discrimination and displayed equal but less selectivity. As expected, atropine did not discriminate between the two responses. The muscarinic antagonists inhibited the McN-A-343-induced responses in a dose-related fashion. Calculation of the ID50s showed that atropine and pirenzepine were equipotent (1.9 vs 2.2 pg kg-' i.v.) whereas trihexyphenidyl and dicyclomine were 10 to 100 times weaker (Table 3) at inhibiting these responses.
Vagally-induced bradycardia and vasodilatation in cats
The muscarinic antagonists showed a wide range of potencies in preventing the decrease of heart rate and hypotension caused by near maximal stimulation of the vagus in cats. Atropine antagonized both vagal effects in a dose-dependent manner with potencies (ID50s 3.6 and 2.1 pg kg-') of the same order of magnitude as that for inhibiting ganglionic stimulation (Table 3) . In contrast, the other antagonists inhibited either action of the vagus at markedly higher doses than those required to reduce the ganglionic effects of McN-A-343 (Table 3 ). The ratio of the ID50s calculated for vagal bradycardia and ganglionic responses, an index of selectivity, was again highest for pirenzepine (90) and lowest for dicyclomine (6).
Discussion
The characterization of muscarinic receptor subtypes is currently the focus of renewed interest and lively debate (Eglen & Whiting, 1985; . As in other systems where potent selective antagonists helped to define the boundaries between subtypes, the classification of the muscarinic receptor has depended significantly on the discriminative properties ofthe tricyclic antagonist pirenzepine. High affinity for this ligand has identified the Ml subtype, whereas low affinity has typified the M2 subtype.
This classification, which has been valuable in understanding the heterogeneity of the receptor, is at present inadequate to explain the accrued evidence. The M2 subtype appears heterogeneous in both functionai and biochemical studies. In fact, cardiac muscarinic receptors differ so extensively from those of smooth muscle and exocrine glands in their properties as to suggest the existence ofdistinct subtypes (Barlow et al., 1976; Stockton et al., 1983; Mutschler & Lambrecht, 1984; Anwar-ul et al., 1986; Giachetti et al., 1986; Hammer et al., 1986) . However, since our study is mainly concerned with drugs interacting with the Ml subtype, the receptors which display low affinity for pirenzepine are generically termed peripheral muscarinic subtypes in the context of this paper.
The results demonstrate that trihexyphenidyl and dicyclomine discriminate between the Ml and the peripheral muscarinic receptors. Both compounds displaced radioligands from membranes derived from various tissues in a manner similar to that of pirenzepine: i.e. high affinity for cortical Ml muscarinic receptors and low affinity for the peripheral receptors ofglands and heart. The ability oftrihexyphenidyl and dicyclomine to discriminate between the Ml and peripheral subtypes was less than pirenzepine, but distinctly greater than atropine. Functional studies further emphasized the similarities between trihexyphenidyl, dicyclomine and pirenzepine. They showed that these drugs inhibit responses mediated by the Ml subtype in sympathetic ganglia in preference to those mediated by peripheral subtypes in the heart and blood vessels. It appears that the muscarinic antagonists, so far examined, fall into two groups. One contains trihexyphenidyl, dicyclomine and pirenzepine, being characterized by a high affinity for the neuronal muscarinic receptor both in biochemical and functional assays. The other group, represented by atropine, and presumably by many of its congeners, displays an undifferentiated type of interaction, hence demonstrating similar affinities for muscarinic receptors of various organs.
Several findings of this study deserve further comment. The potency of trihexyphenidyl and dicyclomine in displacing [3H1-pirenzepine from cortical binding sites was about 3 fold higher than that of pirenzepine, closely approaching that of atropine. A still higher potency relative to pirenzepine, 5 and 15 fold, respectively, was found for dicyclomine and trihexyphenidyl in displacing [3H]-NMS from cardiac membranes. These differences reflect the lower discrimination between receptor subtypes exhibited by the two drugs. The ratio between the IC50s in the heart and cortex indicates the ability of each compound to discriminate between the peripheral receptors and the M1 subtype of the cortex, although analysis of Table 1 illustrates the previously mentioned differences existing within the peripheral subtypes. Among the Ml receptor antagonists examined dicyclomine, for example, shows a lower affinity for the cardiac muscarinic receptor relative to the glandular one, thus revealing substantial (7-8 fold) selectivity between the two.
A comparison of the results obtained in the in vitro binding studies with those from the in vivo pharmacological assays reveals a very large discrepancy between the potency of trihexyphenidyl and dicyclomine in displacing radioligands and in inhibiting either of the muscarinic receptor-mediated responses. For example, both drugs were 1-2 orders of magnitude weaker than pirenzepine in suppressing McN-A-343-induced responses. These changes in potency may be explained by the different pharmacokinetic characteristics of the compounds investigated. Whereas pirenzepine is an exceptionally hydrophilic drug which is poorly metabolized (Eberlein et al., 1977; Hammer & Koss, 1978) , both trihexyphenidyl and dicyclomine are noted for their lipophilic character, possessing an oil/water partition coefficient several orders of magnitude higher than that of pirenzepine (Giachetti, unpublished) . The reduced potency in whole animal experiments may be then attributable primary to a loss of drug from the receptor compartment in favour of lipid structures. These pharmacokinetic considerations do not seem to affect the ability of trihexyphenidyl and dicyclomine to recognize subtypes, since their discriminative property was quantitatively similar whether evaluated in binding or in functional studies.
Recently, the use of McN-A-343 as a selective M,-receptor agonist has been questioned on the grounds that its selectivity may arise from differences in receptor reserve in various tissues (Eglen et al., 1985) . This agent may indeed possess low selectivity coupled with low intrinsic efficacy. However, whatever the mechanism of action of McN-A-343 may be, its utility as a tool to stimulate selectively sympathetic ganglia is sound, since there is evidence for a very high density of the Ml subtype in ganglionic neurones as demonstrated by ligand binding studies Giraldo et al., 1985) and autoradiography (Yamamura et al., 1984) .
An emerging issue in the classification of the muscarinic receptor system is whether the subtypes readily recognized by pirenzepine represent intrinsic differences in receptor proteins. An alternative hypothesis attributes to pirenzepine the ability, unique among antagonists, to induce conformational changes of the same basic protein. These constraining changes would be imposed by the microenvironment surrounding the receptor and vary in different tissues (Berrie et al., 1986) . The origin of subtypes would then be linked to membrane components accessory to the receptor protein which are peculiar for each tissue.
Our approach in trying to learn more about this phenomenon was to examine the behaviour of compounds chemically unrelated to pirenzepine. We re-89 asoned that it would be difficult, although not impossible, for chemically diverse moieties to trigger in the receptor protein identical conformational changes. Although these studies do not allow an unequivocal answer to this problem, they nonetheless provide an interesting clue to the origin of subtypes. The evidence points to the existence of different proteins endowed with specific characteristics.
